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Abstract
Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian
stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new
drugs, treatment options and quantitative methods that can identify single patient characteristics. These could
potentially be used to match patients with the right treatment options to optimise efficacy, safety and tolerability
during COS. Currently, age and follicle-stimulating hormone (FSH) level remain the most commonly used single patient
characteristics in clinical practice. These variables only provide a basic prognosis for success and indications for standard
COS treatment based on gross patient categorisation. In contrast, the anti-Müllerian hormone level appears to be an
accurate predictor of ovarian reserve and response to COS, and could be used successfully to guide COS. The antral
follicle count is a functional biomarker that could be useful in determining the dose of FSH necessary during
stimulation and the success of treatment. Finally, in the future, genetic screening may allow an individual patient’s
response to stimulation during COS to be predicted based on genotype. Unfortunately, despite the predictive power of
these measures, no single biomarker can stand alone as a guide to determine the best treatment option. In the future,
hormonal, functional and genetic biomarkers will be used together to personalise COS.
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Background
Modern medical science has made great advances in the
understanding and treatment of subfertility. This review
is not an evidence-based meta-analysis, but rather pro-
vides our opinion on what we foresee as the future for
controlled ovarian stimulation (COS) and how treatment
protocols could be optimised to improve the outcome
for individual patients. It is worth noting that some of
the studies available in the literature and reported here
have limited sample sizes and may not be adequately
powered to show significance.
Novel technologies have created new ways to evaluate
and treat patients and provide them with a prognosis for
overcoming their subfertility. Basic and clinical research
coupled with advances in technology have led to the devel-
opment of a wide variety of new treatment options,
particularly in the area of COS. Follicle-stimulating hor-
mone (FSH [urinary or recombinant (u-FSH/r-FSH)])
levels can be used alone or associated with luteinising hor-
mone (LH) activity, which in turn can be provided in the
form of human menopausal gonadotrophin (hMG),
recombinant human LH (r-hLH) or human chorionic
gonadotrophin (hCG [urinary or recombinant (u-hCG/r-
hCG)]). In addition, the optional use of steroid hormones
such as progesterone, oestrogen, testosterone or dehydroe-
piandrosterone (DHEA), and even the possibility of growth
hormone treatment, could be considered following further
research. Taken together, all these options tend to increase
the complexity of treatment decisions. The discussion
around gonadotrophin-releasing hormone (GnRH) agonist
versus antagonist protocols during COS is another exam-
ple highlighting the expanding number of treatment
options and the urgent need to develop a rationale for
making the best choice of treatment for each single
patient.
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the primary sources of information used to provide a
prognosis and guide treatment. Along with basic medical
and nutritional information, functional, hormonal and
genetic biomarkers are tools that could provide more
accurate diagnostic and prognostic information. Nonethe-
less, there is currently no consensus in the literature
around the world as to how these newly available tools
should be applied for a personalised treatment plan in
order to improve the outcome of COS. Presently, general
patient characteristics determine treatment, disregarding
unique characteristics that might influence the needs of
the individual patient, and thus, the chance of success.
Empirical decision-making based on broad generalisations
translates to similar patients receiving similar treatments.
Thus, conventional factors like age and previous cycle data
are used to make vital treatment decisions. Quantitative
biomarkers are utilised mainly to predict prognosis and to
inform patient counselling, but the strong potential of
these indicators as tools to personalise COS is often
underestimated [1].
The multidimensional variability of the subfertile patient
population renders a single treatment approach unsuitable
to dealing with a wide range of patient characteristics.
This diversity in the fertility patient population, together
with the ever-expanding number of treatment options
(Table 1), creates both the need and the opportunity for
personalised treatment, including an individualised
approach to COS. The goal of ‘personalised COS’ can be
achieved by taking advantage of the information provided
by advancing science and new technologies. Using hormo-
nal, functional and genetic biomarkers to develop a stan-
dard method of customising COS will make it possible to
consistently match the correct treatment to the right
patient. The improvements in treatment decision-making
will lead to less burdensome protocols, less risk of adverse
events, better outcomes and cost efficiency.
How can we predict ovarian response and
personalise treatment?
Age versus biomarkers
Age is the most commonly used predictor of fertility;
increasing age inevitably results in substantial germ cell
loss by the age of 40 [2]. Statistics for pregnancy, live
birth and singleton live birth rate also decline rapidly
from the mid-thirties on [3]. However, even though age
is clearly linked to declining fertility, it does not affect all
women equally. On an individual basis, the chronological
age of an individual may not be as valuable a predictor of
fertility as their ‘biological age’, which is defined by the
hormonal and functional profiles. Thus, biomarkers
quantifying hormonal and functional profiles are more
useful as prognostic factors than age alone when predict-
ing response and choosing treatment strategy. Finally,
genetic screening can provide specific information about
aw o m a n ’sr e p r o d u c t i v es y s t e mt h a tw o u l dn o tb ea c c u -
rately predicted by age, hormonal or functional biomar-
kers. By considering hormonal (FSH and anti-Müllerian
hormone [AMH]), functional (antral follicle count
[AFC]), and genetic biomarkers in combination, a com-
plete picture of an individual patient’so v e r a l lr e p r o d u c -
tive status can be formulated to provide a basis of
designing an optimal treatment plan.
Hormonal biomarkers: AMH
Inhibin-B, FSH and AMH are hormonal markers that
can be used to predict ovarian response to COS and
success with assisted reproductive technology (ART).
Table 1 Variables in the choice of COS protocol
Factors determining individual patients’ response to
ovarian stimulation
Treatments used in ovarian
stimulation protocols
Protocol variations
Demographics and anthropometrics
(e.g., age, BMI and race)
Gonadotrophins:
r-FSH/LH/hCG
u-FSH/LH/hCG
GnRH agonist protocol
(long, short and micro flare)
Genetic profile GnRH analogues:
Agonists
Antagonists
GnRH antagonist protocol
(standard, mild and modified natural)
Health status Steroid hormones:
Progesterone
Oestradiol
Testosterone
DHEA
Agonist-antagonist protocol
Cause of subfertility Other treatments:
Aromatase inhibitors
Growth hormone
Clomiphene citrate
Natural cycles
Duration of subfertility
Nutrition
BMI = body mass index; COS = controlled ovarian stimulation; DHEA = dehydroepiandrosterone; GnRH = gonadotrophin releasing hormone; hCG = human
chronic gonadotrophin; LH = luteinising hormone; r-FSH = recombinant follicle-stimulating hormone; u-FSH = urinary follicle-stimulating hormone.
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ate a woman’s probable response to COS, AMH (as a
paracrine product of immature follicles) is a more direct
measure of ovarian status compared with other endo-
crine reproductive hormones. AMH is primarily pro-
duced by the pre-antral and small antral follicles, and
correlates with the number of primordial follicles at the
gonadotrophin-independent stage of follicular develop-
ment [4,5].
A small study showing the potential use of AMH mea-
surement in a routine in-vitro fertilisation (IVF) pro-
gramme prospectively enrolled 316 patients and
considered 132 oocyte retrievals in women undergoing a
GnRH agonist long protocol. When the calculated opti-
mal AMH cut-off of ≤1.26 ng/ml was used to predict
responses to COS, it was found to have a 97% sensitivity
for predicting poor responses (< 4 oocytes retrieved) and
a 98% accuracy in predicting a normal COS response.
These findings indicate that circulating AMH levels may
be a good indicator of ovarian reserve, and are highly
correlated with ovarian response to COS [6].
In the first study designed to evaluate the use of a
hormonal biomarker to determine treatment strategy,
Nelson and colleagues compared the safety, tolerability
and success rates of different AMH-based COS strate-
gies in two IVF centres. In this prospective cohort
study, 538 women were stratified according to their
AMH levels prior to COS (low: 1- < 5 pmol/l, medium:
5-15 pmol/l and high: > 15 pmol/l). In both centres,
doses were similarly determined by each patient’sA M H
level; high, medium or low doses of FSH were given to
women with low, medium and high AMH levels, respec-
tively. However, in one centre, the choice between the
GnRH agonist long protocol versus a milder GnRH
antagonist protocol was also determined based on AMH
levels. Specifically, most patients at the first centre
(regardless of AMH level) were treated with a GnRH
agonist long protocol, while in the second centre, those
with high or low AMH levels were treated with a GnRH
antagonist protocol.
In both centres, low AMH levels were associated with a
reduced clinical pregnancy rate (CPR), but the cohort of
low AMH patients receiving the antagonist protocol had
a median duration of treatment of 10 days with a cancel-
lation rate of 5% compared with a duration of 14 days
and cancellation rate of 19% for the group treated with
GnRH agonist long protocol. As expected, women from
both centres with normal AMH levels had similar good
outcomes with no poor response and no incidence of
excessive stimulation. However, the group of patients
with high AMH levels, similar to the group with low
AMH levels, had better outcomes using the GnRH
antagonist compared with the agonist protocol. No
patients with high AMH who underwent the GnRH
antagonist protocol were hospitalised due to ovarian
hyperstimulation syndrome (OHSS) compared with
13.9% in the high AMH level group who received the
GnRH agonist long protocol. In addition, use of the
antagonist protocol did not result in any cases of ‘total
freeze’ to avoid OHSS. Furthermore, the improvements
in COS safety and tolerability observed with the GnRH
antagonist protocol were accompanied by higher CPRs in
both the low AMH (11.1% vs 18.7%) and high AMH
(40.1% vs 63.6%) groups [7]. The data from this study
should be confirmed in large, randomised, controlled
trials, but suggest that AMH may be used as a precise
and reliable predictive tool to determine treatment strate-
gies that can improve safety, tolerability and pregnancy
outcomes (Figure 1).
Currently, a limiting factor in the use of AMH as a
biomarker is the variability seen between commercial
kits and variation in results reported from different
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Figure 1 Treatment strategies and predicted response to COS based on patient circulating AMH levels. Treatment strategies (right
column) and predicted response to COS (middle column) based on patient circulating AMH levels (left column). AMH = anti-Müllerian hormone;
COS = controlled ovarian stimulation; GnRH = gonadotrophin releasing hormone; CPR = clinical pregnancy rate; OHSS = ovarian
hyperstimulation syndrome; FSH = follicle-stimulating hormone.
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sons for the lack of consensus on the cut off values of
AMH when deciding whether or not to proceed with
ART.
Functional biomarkers: AFC
The number of antral follicles detected by ovarian ultra-
sound has gained acceptance as an indicator of ovarian
reserve, a COS response prognostic tool and predictor
of IVF success [9,10]. In a study including 149 treatment
cycles, Chang and colleagues found that AFC declined
with age and was negatively correlated to day 3 FSH
and cancellation rate. In the same study, when patients
were grouped by AFC (AFC < 4, 4-10 or > 10), the
mean number of retrieved oocytes was 2.0, 6.3 and 14.0,
and ongoing pregnancy rates were 0%, 13.2% and 26.3%,
respectively [11].
Another study investigated 113 women undergoing
their first ART cycle. In this group, AFC was found to
be significantly associated with AMH levels and the
number of retrieved oocytes, with the number of folli-
cles between 5 and 6 mm having the highest correlation
to both endpoints. AFC was also found to be predictive
of poor responses to COS, with the number of follicles
sized 2-4 mm, 2-5 mm, 2-8 mm and 2-10 mm being
approximately equal in predicting response [12].
AFC is a relatively easy-to-perform technique that is
widely accessible due to the availability of ultrasound
equipment. Despite its general acceptance as a predictor
of ovarian response, the routine use of AFC has been ham-
pered by the lack of a standard methodology that would
permit valid comparisons of data from different centres,
and thus facilitate the consistent assessment of AFC. In
order to address this issue, Broekmans and colleagues sug-
gested recommendations for the standardisation of AFC
assessment in routine clinical practice. Basic clinical and
technical requirements for AFC evaluation were defined
and a systematic method of measuring and counting antral
follicles in clinical practice was proposed (Table 2) [13].
Hopefully, as these guidelines are adopted around the
world, the accumulation of standardised, universally rele-
vant AFC data will make this quantitative, functional bio-
marker an even more useful prognostic tool.
Similarly to AMH, AFC was initially used as a simple
prognostic factor and subsequently become a decision-
making variable. Following the initial establishment of
AFC as a reliable prognostic factor, its use in matching
patients with COS protocols was hypothesised. A first
Table 2 The basic clinical and technical requirements for assessment of the AFC in clinical practice (reproduced with
permission from Broekmans et al.
Considerations for the assessment of the AFC in clinical practice
Clinical considerations Technical considerations
Select patients with regular menstrual cycles with no co-existing
pathological condition that could technically affect the counting of
follicles, such as ovarian endometriosis or previous ovarian surgery
A limited number of personnel, appropriately trained in transvaginal
sonography should perform AFCs in each unit
Real-time, two-dimensional imaging is adequate
Count follicles between days 2 and 4 of a spontaneous menstrual
or oral contraceptive cycle to avoid the effect of intra-cycle variation
Include all antral follicles of 2-10 mm in diameter
Use a transvaginal transducer
Use a probe with a minimum frequency of 7 MHz, which is
maintained in an adequate condition and able to resolve a structure
of 2 mm in diameter
Use a systematic process for counting antral follicles:
1. Identify the ovary
2. Explore the dimensions in two planes (perform a scout sweep)
Decide on the direction of the sweep to measure and count follicles
3. Measure the largest follicle in two dimensions
A. If the largest follicle is ≤10 mm in diameter:
i. Start to count from outer ovarian margin of the sweep to
the opposite margin
ii. Consider every round or oval transonic structure within
the ovarian margins to be a follicle
iii. Repeat the procedure with the contralateral ovary
iv. Combine the number of follicles in each ovary to obtain
the AFC
B. If the largest follicle is > 10 mm in diameter:
i. Further ascertain the size range of the follicles by
measuring each sequentially smaller follicle, in turn, until a
follicle with a diameter of ≤10 mm is found
ii. Perform a total count (as described) regardless of follicle
diameter
iii. Subtract the number of follicles of > 10 mm from the
total follicle count
2010 [13])
AFC = antral follicle count.
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of Reporting Trials (CONSORT) analysis, which aimed
to determine whether specific factors could optimally
predict a response to stimulation in ART and then
develop a treatment algorithm to determine the optimal
starting dose of r-FSH [14]. Results from a subsequent
CONSORT study demonstrate that AFC, combined
with other patient characteristics, can be used to perso-
nalise treatment and maximise COS response and, at
the same time, minimise patient risk and treatment bur-
den [15]. The CONSORT dosing algorithm was used to
calculate the dose of r-FSH with 37.5 IU incremental
increases based on basal FSH, body mass index (BMI),
age and AFC. Patients were assigned to r-FSH doses of
75 IU (n = 48), 112.5 IU (n = 45), 150 IU (n = 34),
187.5 IU (n = 24) and 225 IU (n = 10). Oocytes
retrieved per cycle were 8.5, 8.0, 10.0, 12.0 and 8.0, and
CPRs per cycle of 31.3%, 31.1%, 35.3%, 50.0% and
20.0%, respectively, were observed [15]. The favourable
retrieval and pregnancy rates seen in this preliminary
study demonstrate the successful use of multiple bio-
markers, including AMH, to achieve effective individua-
lised COS (Figure 2).
Genetic biomarkers
The influence of genetic research continues to shape the
scientific and medical landscape. Pharmacogenetics is
the science of predicting drug effects based on the geno-
type of an individual. In the future, the treatment of a
patient could be based on her individual DNA. Pre-
sently, even though the biological response to any given
drug may be influenced by hundreds of genes, progress
is being made in the identification of specific genetic
variances, called single nucleotide polymorphisms
(SNPs) that can predict the safety and effectiveness of
certain drugs in individual patients. In the field of repro-
ductive health, hormonal and functional biomarkers are
more established as tools to predict ovarian response,
but in the future, genetic biomarkers may well be the
best predictive tool to guide individualised treatment.
Genetic traits that influence fertility may not have visi-
ble clinical signs or abnormalities. If a patient’s genetic
profile also diminishes her response to fertility treatment,
the failure to consider the genotype when designing the
treatment consequently leads to a suboptimal treatment
strategy. For example, a subset of young, normogonado-
trophic IVF patients may produce an adequate number
of retrieved oocytes and normal oestrogen levels, but not
respond to COS as anticipated. These women require
high doses of FSH (> 2,500 IU) over long treatment peri-
ods and, despite good prognostic indicators, have low
implantation and pregnancy rates [16-19]. One possible
reason for this hyporesponder ‘normal’ population is that
they may have a genetic predisposition to a reduced sen-
sitivity to FSH.
FSH and LH synergistically regulate normal ovarian
function and oocyte development, and the disruption of
either hormonal signal could have an impact on normal
ovarian function and stimulation response. Thus, the
genetic variability that affects the innate activity of these
hormones could provide valuable predictive information
and help guide COS treatment choices. Mutations in
the genes coding for LH [20-24], the LH receptor
[25-27] and the FSH receptor [28-32] have been identi-
fied as possible causes of subfertility, as well as factors
that may influence fertility treatment.
A common variant of the b subunit of the LH mole-
cule (v-LH) is identified by an additional sulphonated
sugar at asparagine (Asn)-13 [33]. The v-LH polymorph-
ism is found in populations worldwide, but has so far
been most commonly identified in northern European
countries [34]. There is clear clinical evidence that the
v-LH polymorphism affects FSH sensitivity and the
ovarian response to COS. For example, in a group of 60
normogonadotrophic women aged 18-37 years with nor-
mal menstruation, basal FSH ≤1 0I U / la n da tl e a s tf i v e
oocytes retrieved, one homozygote and seven v-LH het-
erozygotes were identified. When these women were
s t r a t i f i e db yt h ec u m u l a t i v ed o s eo fF S Hu s e d( >3 , 5 0 0
IU, 2,000-3,500 IU or < 2,000 IU), one heterozygote fell
in the middle range with the rest having had doses
greater than 3,500 IU [24]. In another study of 204 nor-
mogonadotrophic women, 21 v-LH heterozygotes and
three v-LH homozygotes were identified. The FSH dose
needed was positively correlated with the presence of
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Figure 2 Treatment strategies and predicted response to COS
based on patient circulating AMH levels. Pregnancy outcomes
after COS with r-FSH doses determined by basal FSH, BMI, age and
AFC using the CONSORT dose calculator algorithm. AFC = antral
follicle count; FSH = follicle-stimulating hormone; ASN = asparagine;
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680; BMI = body mass index; CONSORT =
Consolidated Standards of Reporting Trials; COS = controlled
ovarian stimulation; r-FSH = recombinant follicle-stimulating
hormone. Adapted from Olivennes et al. 2009 [14].
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zygotes and heterozygotes received a substantially higher
cumulative dose when compared with the wild-type car-
riers (Figure 3) [35]. These preliminary analyses suggest
that the v-LH genotype may help identify a subgroup of
potential COS hyporesponders who are less sensitive to
FSH, and who would benefit from LH supplementation
rather than stimulation with higher doses of FSH.
Hyposensitivity to FSH may also be caused by a genetic
variant of the FSH receptor. Two FSH receptor variants
that have SNPs in the coding region have been identified
and well characterised [36]. The SNP known as the Ser-
ine
680 (Ser
680) variant causes the replacement of Asn
with Ser at the 680 position, which is located in the intra-
cellular domain of the FSH receptor protein [37]. Consis-
tent with reduced sensitivity to endogenous FSH, carriers
of this trait have higher FSH levels throughout most of
the menstrual cycle, and a significant increase in both
total menstrual cycle length and number of antral folli-
cles [29]. When this SNP was studied in a group of 161
women below the age of 40 years undergoing ART, the
distribution was 45% for the wild-type (Asn/Asn), 29%
for the heterozygote (Asn/Ser
680) and 26% for the homo-
zygote (Ser
680/Ser
680). Although peak oestradiol levels,
numbers of pre-ovulatory follicles and numbers of
retrieved oocytes were similar in the three groups, basal
FSH levels were significantly higher for carriers of the
Ser
680 variant (6.4 IU/l, 7.9 IU/I and 8.3 IU/l for the Asn/
Asn, Asn/Ser
680 and Ser
680/Ser
680 groups, respectively).
Furthermore, both the heterozygotes and homozygotes
required significantly more FSH during COS compared
w i t ht h ew i l d - t y p eg r o u p( F i g u r e4 )[ 3 8 ] .T h es e c o n d
receptor variant, known as the Alanine
307 (Ala
307)v a r -
iant, is generated through substitution of threonine (Thr)
with Ala at the 307 position, located in the extracellular
domain of the FSH receptor [37]. There is a very strong
linkage disequilibrium between the two SNPs. This
means that women who possess Thr
307 nearly always
have Asn
680 present on the same allele, and women who
have Ala
307 have Ser
680 on the same allele [36]. The link
between FSH receptor SNPs and polycystic ovarian sti-
mulation (PCOS) has been studied extensively; however,
there is some variation in the results seen. Some studies
have demonstrated higher levels of patients with Ser
680 in
the PCOS population [39], whereas other investigators
have shown differences in basal levels of FSH depending
on the presence of the SNP [40]. Interestingly, it has
recently been demonstrated that PCOS patients with the
Ser
680 mutation have a natural resistance to clomiphene
citrate [41]. This may prove to be very important in the
field of ovarian stimulation in the future with clinicians
devising their COS protocols according to factors includ-
ing FSH receptor genotype. Additionally, the effect of the
Ser
680 SNP has been studied in the general population
receiving subfertility treatment and results have been
reviewed previously [42]. Studies have reported conflict-
ing results with some demonstrating worse outcomes
with the mutation and others demonstrating positive out-
comes. For example one study demonstrated higher preg-
nancy rates in the patients with Asn680 [43] and another
showed higher pregnancy rates in patients with Ser680
[44].
An additional study looked at FSH-induced oestradiol
levels in women who were homozygous for the Ser
680 var-
iant compared with women with the wild-type (Asn/Asn).
This represented the first attempt to develop a pharmaco-
genomical approach to COS. Ser
680/Ser
680 carriers were
randomly allocated to two subgroups to receive a daily
FSH dose of 150 IU or 225 IU, respectively. Age and BMI-
matched Asn/Asn carriers, receiving a daily dose of 150
IU, constituted a third (control) group. Even though the
treatment details, number of oocytes retrieved and fertili-
sation rates were similar, the wild-type group had higher
oestradiol production after treatment with 150 IU/day of
Asn/Asn
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680 group given the same dose;
conversely, when Ser
680/Ser
680 carriers were treated with
225 IU/day, this difference disappeared [31]. These find-
ings are consistent with carriers of the Ser
680/Ser
680 var-
iant experiencing lower biological activity of both
endogenous and exogenous FSH due to lower sensitivity
of the FSH receptor to FSH. However, it should be noted
that two further studies did not confirm that adjustment
of the starting dose of FSH improved the hormonal
response [43,44]. Despite this, the findings of FSH starting
dose modification studies raise an intriguing question
about the interpretation of isolated markers, including
AFC. In fact, the current literature suggests that AFC is
effective in predicting ovarian response and choosing the
right FSH dose; nevertheless, a pharmacogenomical
approach to COS strongly indicates that, in at least one
out of four patients with normal AFC (which reflects the
frequency of Ser
680/Ser
680), the optimal FSH dose should
be higher. This provides further support that AFC and
genetic approaches should be integrated into determina-
tion of COS treatment protocols.
In addition to the two SNPs described above, there are
also many genotypic SNPs found in the introns and
untranslated regions of the FSH receptor gene; however,
it is not currently known what physiological effects
these mutations confer [36]. Further mutations have
been identified in young women (< 35 years) undergoing
COS in the form of receptor splice variants [32]. FSH
receptor messenger RNA was isolated from the cumulus
cells of women who demonstrated high or low response
to FSH when treated with a GnRH agonist long proto-
col. Abnormal splicing products were identified that
affected the ligand-binding extracellular domain. One
variant was associated with a low response to FSH, and
another variant was associated with a high FSH response
[32].
Patient profiling
Each patient’s individual characteristics must be consid-
ered in order to determine treatment that will provide her
with an optimal response to COS, while keeping the
adverse events and treatment burden as low as possible.
Specifically, the hormonal, functional and genetic biomar-
kers described here can provide the critical information
needed to personalise treatment to best serve the
individual patient. AMH represents ovarian reserve and
can help determine how much longer a woman will
remain fertile and if ART is a viable option. AFC repre-
sents the number of follicles that are maturing in each
cycle and provides a prediction of the response to COS.
Finally, the individual patient’s genetic profile defines the
underlying physiology that determines the meaning and
interpretation of hormonal and functional biomarkers like
AMH and AFC, predicting the effectiveness of FSH when
stimulating the ovaries (Table 3).
In addition to using the patient’s individual characteris-
tics to determine which treatment protocols should be
selected, this patient-specific approach could potentially
be used to determine how treatment protocols are admi-
nistered. The short, ultrashort, micro-flare and stop GnRH
agonist protocols are all adaptations of the standard proto-
col for COS, generated by adjusting the timing and dose of
GnRH agonist administration [45,46]. Preparation of the
endometrium is also a crucial step in the success of IVF.
Further analysis of hormonal, functional and genetic bio-
markers and their relationships with patient response to
variations in treatment protocols could be used in the
future, and additional clinical data are required to support
this hypothesis.
Conclusions
Individual patient characteristics can be predictive of
ovarian response, and these factors must be used to
optimise the individual treatment regimen. AMH and
AFC are good predictors of ovarian response to COS,
and may be valuable in deciding which protocol and
dose to use for COS. Additionally, initial data indicate
that the use of AMH to determine protocol selection
m a yr e d u c et h ei n c i d e n c eo fO H S S ,a l t h o u g hf u r t h e r
studies are required to confirm this. The hyposensitivity
to FSH in a subset of women undergoing the GnRH
agonist protocol despite other normal indicators was
described by De Placido and colleagues [17]. It is possi-
ble that this condition may be caused by genetic poly-
morphisms of LH, the FSH receptor or the LH receptor.
Thus, genetic testing of normogonadotrophic women
showing reduced sensitivity to FSH (e.g., a high FSH
dose in previous cycles) may assist in tailoring subse-
quent treatment. Patients could be given higher doses of
FSH if they are found to carry the Ser
680 variant, or
Table 3 Patient genetic profiles: interpretation of physiology and biomarker levels
Genetic profile Interpretation of genetic profile
Low AMH levels; low AFC Suggests that even high doses of FSH would be ineffective and that LH would not improve results
Patient would benefit from counselling to better understand her limited chances of success
FSH receptor variant (eg. Ser
680); good AMH
levels; good AFC
Suggests a good prognosis, but it also predicts a genetic hyposensitivity to FSH that should be
considered when formulating COS treatment
v-LH (variant in b subunit of LH receptor) Suggest that a patient might benefit from LH supplementation during COS
AMH = anti-Müllerian hormone; AFC = antral follicle count.
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carry the v-LH polymorphism. As technology progresses
and more powerful analytical tools are developed, pre-
dicting ovarian response using a single biomarker will
not be sufficient to make the most accurate prognosis
or to formulate a personalised treatment plan. In the
future, the combination of hormonal, functional and
genetic testing will be needed to ensure that the right
treatment protocol is provided to the right patient.
Finally, the patient’s response to treatment should be
monitored closely to determine if further tailoring of the
personalised treatment plan is required.
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